Souhaitez-vous accéder aux communiqués récents ?

Créez un compte lecteur dès aujourd’hui afin de suivre les secteurs et les entreprises qui vous intéressent, et configurer votre tableau de bord.

Se Connecter À Un Compte Lecteur Créer Un Compte Lecteur

01 févr. 2024 16h30 HE | Source: Certara

Certara to Report Fourth Quarter and Full Year 2023 Financial Results on February 29th, 2024 and Participate in the Barclays 26th Annual Global Healthcare Conference

PRINCETON, N.J., Feb. 01, 2024 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the fourth quarter and...
13 déc. 2023 16h30 HE | Source: Certara

Certara Acquires Applied BioMath Expanding Its Biosimulation Portfolio to Industrialize New Capabilities for Optimal Dosing for Novel Therapies

Combined Certara-Applied Biomath organization establishes the life sciences industry’s largest quantitative systems pharmacology center.
21 nov. 2023 16h30 HE | Source: Certara

Certara introduces Simcyp™ Biopharmaceutics software to increase efficiency of novel and generic drug formulation & development

Certara's Simcyp™ Biopharmaceutics software helps biopharmaceutic, formulation & CMC scientists formulate complex new and generic drugs faster and cheaper.
08 nov. 2023 16h10 HE | Source: Certara

Certara Reports Third Quarter 2023 Financial Results

PRINCETON, N.J., Nov. 08, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the third quarter of fiscal year 2023. ...
11 oct. 2023 16h15 HE | Source: Certara

Certara to Report Third Quarter 2023 Financial Results on November 8th, 2023, and participate in the Stephens Annual Investment Conference

PRINCETON, N.J, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the third quarter of 2023...
19 sept. 2023 08h15 HE | Source: Certara

Certara Announces 300th Regulatory Submission Milestone Using its Technology-enabled Services and Software

PRINCETON, N.J., Sept. 19, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced it has successfully supported 300 completed submissions to...
29 août 2023 16h15 HE | Source: Certara

Certara to Participate in Upcoming Investor Conferences

PRINCETON, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that Company management will participate in the following investor...
29 août 2023 08h15 HE | Source: Certara

Certara Simcyp™ Group Awarded Two New Grants from US FDA

PRINCETON, N.J., Aug. 29, 2023 (GLOBE NEWSWIRE) -- Certara (Nasdaq: CERT), a global leader in biosimulation, today announced that the Simcyp group has been awarded two new grants from the U.S. Food...
09 août 2023 16h15 HE | Source: Certara

Certara Reports Second Quarter 2023 Financial Results

PRINCETON, N.J., Aug. 09, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today reported its financial results for the second quarter of fiscal year 2023. ...
13 juil. 2023 16h30 HE | Source: Certara

Certara to Report Second Quarter 2023 Financial Results on August 9th, 2023

PRINCETON, N.J., July 13, 2023 (GLOBE NEWSWIRE) -- Certara, Inc. (Nasdaq: CERT), a global leader in biosimulation, today announced that it will release financial results for the second quarter of...

Page précédente